Background: A previous randomized study showed that clarithromycin decreases the risk of death due to ventilator-associated pneumonia and shortens the time until infection resolution. The efficacy of clarithromycin was tested in a larger population with sepsis.
Introduction
Sepsis is a leading cause of death. It usually affects the elderly with serious underlying disorders, but also young people with multiple injuries or those that are otherwise healthy. This leads to estimations that .1.5 million people develop severe sepsis and septic shock annually in the USA and a similar number of people in Europe. 1, 2 Mainstays of management are early diagnosis and the early administration of fluids and antimicrobials. 3 Despite this strategy, mortality may exceed 50% for cases of septic shock. In many countries, this is aggravated by the shortage of beds in intensive care units (ICUs). The burden of sepsis has led to the development of agents that intervene in the pathogenesis of sepsis by modulating inflammation and coagulation. Most clinical trials of these agents have failed to demonstrate benefit, with the PROWESS-SHOCK study as a recent example. 4 Macrolides are narrow-spectrum antimicrobial agents with considerable anti-inflammatory properties. Analyses of retrospective data suggest that adding a macrolide to the treatment of severe community-acquired pneumonia (CAP) leads to decreased mortality. 5, 6 There is a lack of evidence from randomized trials. We have been the only group to conduct a double-blind, placebo-controlled, randomized clinical trial, in 200 patients with ventilator-associated pneumonia (VAP). In addition to standard therapy, we allocated patients to placebo or clarithromycin treatment for 3 days. Clarithromycin does not have any antimicrobial effect on the multidrug-resistant Gram-negative isolates that caused VAP in the study population. Treatment with clarithromycin was of major benefit in decreasing the risk of death due to septic shock and multiple organ dysfunctions (MODS) and in decreasing the time until resolution of VAP and until weaning from mechanical ventilation. 7 These positive results prompted us to perform a new trial with intravenous clarithromycin as adjunctive treatment in patients with Gram-negative sepsis. Patients with microbiologically confirmed or clinically suspected Gram-negative sepsis were enrolled, since clarithromycin lacks activity against Gram-negative bacteria. The specific questions that we wanted to address were if adjunctive treatment with clarithromycin may (i) impact on the final outcome of the more severe patients; (ii) decrease the duration of hospital stay; and (iii) decrease hospitalization costs.
Patients and methods

Trial design
This was a prospective, double-blind, randomized, placebo-controlled, multicentre clinical trial of the efficacy of adjunctive treatment with clarithromycin over placebo in patients with suspected Gram-negative sepsis. The study protocol was approved by the National Ethics Committee of Greece (approval 42797/20-06-2007) and the National Organization for Medicines of Greece (approval 76305/15-02-2007). The study is registered (EudraCT number: 2006-004886-33; http://clinicaltrials.gov number: NCT01223690). The allocation to the two treatment arms was 1 : 1. No changes to the study protocol were made during the study conduct.
Participants
The inclusion criteria were (i) written informed consent by the patients or by the first-degree relatives for patients unable to consent; (ii) age ≥18 years old; (iii) at least two signs of the systemic inflammatory response syndrome (SIRS); and (iv) presence of one of the following infections: primary Gramnegative bacteraemia, acute pyelonephritis or acute intra-abdominal infection.
The exclusion criteria were (i) neutropenia defined as ,500 neutrophils/ mm 3 ; (ii) HIV infection; (iii) oral intake of corticosteroids at a dose ≥1 mg/kg equivalent prednisolone for a period .1 month; and (iv) intake of any macrolide as treatment for the current infection episode.
The following signs of SIRS were considered for study enrolment: 8 (i) core temperature .388C or ,368C; (ii) pCO 2 ,32 mmHg or .20 breaths/min; (iii) pulse rate .90/min; and (iv) white blood cells .12000/mm 3 , ,4000/ mm 3 or .10% of band forms. Core temperature was measured on admission and during hospitalization in all study sites every 3 h by digital ear thermometers (Braun Thermoscan, Welsch Allyn, Athens, Greece). Diagnosis of primary Gram-negative bacteraemia, of acute pyelonephritis and of acute intra-abdominal infections was made according to standard definitions. 9, 10 The study was conducted between July 2007 and April 2011 in six departments across Greece: three departments of medicine, two ICUs and one department of surgery.
Patients were followed up for 28 days. They were graded into sufferers from uncomplicated sepsis, severe sepsis and septic shock according to standard definitions. 8 The following information was recorded at baseline and on follow-up: (i) vital signs; (ii) Acute Physiology and Chronic Health Evaluation II score; (iii) laboratory exams; (iv) blood gases and the pO 2 / FiO 2 ratio; (v) chest X-ray; (vi) failing organs; (vii) administered antimicrobial agents, vasopressors, hydrocortisone and insulin; (viii) isolated pathogens from any biological specimen; (ix) all coadministered medications; (x) need for source infection control either by percutaneous interventions or by intra-abdominal operation; (xi) serious adverse events (SAEs) and non-SAEs; and (xii) resolution of infection. Diagnosis of organ failures was made according to standard definitions. 8 MODS was defined as the presence of at least two organ failures necessitating intervention to maintain homeostasis. 8 A patient was considered to be receiving appropriate antimicrobial therapy when at least one of the administered antimicrobials was active against the isolated pathogen according to the antibiogram. Daily visits were made at the same time as the administration of the first dose of the study drug. The cost of hospitalization (accommodation, drugs, laboratory exams, radiology exams and interventions) was recorded after the discharge of the patient and provided to the assigned blinded monitor (M. M.) by the handlers of the central electronic database of each hospital (MedISys # 2004, Athens, Greece). SAE was considered any unexpected event that (i) led to death; (ii) put the patient's life in danger; (iii) prolonged hospitalization; (iv) was accompanied by permanent or considerable disability; or (v) any grade IV laboratory abnormality. Organ failures and death related to sepsis were not assessed as SAEs.
Resolution of primary bacteraemia was assigned on the day where (i) no signs of SIRS were apparent; and (ii) blood cultures remained sterile for ≥5 days after diagnosis. Resolution of acute pyelonephritis was assigned on the day where (i) no signs of SIRS were apparent; (ii) clinical signs of pyelonephritis leading to study enrolment ceased to exist; and (iii) no indications of pyuria and of bacteriuria were available. Resolution of an intra-abdominal infection was assigned on the day where (i) no signs of SIRS were apparent; and (ii) radiological signs of infection leading to study enrolment ceased to exist.
All clinical information was recorded into a case report form (CRF). All CRFs were confirmed by the blinded monitor (M. M.).
Interventions
Patients were randomly assigned to receive either placebo or clarithromycin treatment. The study drug was administered once daily within 1 h for four consecutive days. For patients allocated to the clarithromycin arm, 1 g was administered once daily in agreement with our former study. 7 Two vials containing 500 mg clarithromycin each (Abbott, Ludwigshafen, Germany) were dissolved in 20 mL of water for injection each and diluted to a final volume of 250 mL in glucose 5% in water. Placebo consisted of 20 mL of water for injection diluted to 250 mL in glucose 5% in water. The final dilutions of placebo and of clarithromycin had the same colour. Administration was done by an infusion pump at 4.16 mL/min through a catheter connected to a peripheral vein or to a central vein if possible.
Outcomes
The primary endpoint was the effect of clarithromycin on mortality and risk of death due to severe sepsis/shock and MODS compared with placebo after Giamarellos-Bourboulis et al.
28 days. The secondary endpoints were the effects of clarithromycin compared with placebo on the time to resolution of the infection and on the time to progression to MODS. No changes to the trial outcomes were made after the trial commenced.
Sample size
Taking into consideration (i) the study primary endpoint; and (ii) the mortality of the control group being expected to be 25%, assigning 80% power to achieve a .10% two-sided difference between the two arms of treatment regarding the relative risk (RR) for death due to severe sepsis/shock, it was found that 300 patients should receive placebo and 300 clarithromycin. The steering committee comprised by authors E. J. G. B., I. K., C. G., E. E. D., G. K. and A. Armaganidis assessed the mortality of the entire study population in a blinded fashion at 3 month intervals and since no deviation was observed from the expected rate, no interim analysis was performed.
Randomization
The allocated sequence was generated by an independent biostatistician. A separate sequence was generated for each study site. Sealed envelopes were used to implement the allocation sequence. The study drug was prepared by the unblinded investigator (M. R.) who had access to the randomization table. This investigator kept the records for drug administration in a locked drawer and no other copies were kept. The lack of involvement of this investigator with any other study procedure was ascertained by the members of the steering committee. Once prepared, the study drug was delivered to one blinded nurse for administration. Enrolment of patients was done by V. M., A. A., I. T., P. K., B. P., T. T., F. B., P. Koutoukas, A. Spyridaki and N. M.
Blinding
Members of the steering committee (E. J. G. B., I. K., C. G., E. E. D., G. K. and A. A.), investigators who enrolled patients (V. M., A. A., I. T., P. K., B. P., T. T., E. P., F. B., P. Koutoukas, A. Spyridaki and N. M.), investigators who completed the CRFs and assessed final outcomes (A. M., K. L., C. P., A. P. G., E. P., M. L., A. S., A. P., T. K., A. K. and I. V.), the study monitor (M. M.), nursing personnel, attending physicians and patients were blind to the administered intervention by not having any access to the randomization table. Unblinding for the study drug was done when follow-up of all patients was completed.
Statistical analysis
Comparisons of baseline characteristics between groups were done by the x 2 test for qualitative variables and by Student's t-test or the MannWhitney U-test for quantitative variables with normal or non-normal distribution, respectively.
Per protocol analysis described that the RR for death under the influence of risk factors would be defined separately within placebo-treated patients and within clarithromycin-treated patients and compared. Protocol also required that analysis should be done in light of the underlying sepsis severity. RRs and corresponding 95% CIs were calculated by Mantel-Haenzel's statistics; comparisons of RRs between treatment groups were done using the Altman-Bland interaction test. 11 Comparison of the death rate by septic shock and MODS between the two groups was done by the binomial test.
Survival analysis and analysis of time until resolution of the infection and until progression to MODS was done by the Kaplan-Meier method; comparisons were done by Mantel-Cox's log-rank test. To define the impact of risk factors on the final outcome and the role of clarithromycin treatment as a moderator of the outcome, logistic regression analysis was performed. Final outcome at 28 days (survival/death) was the dependent variable; organ failures and the interaction of organ failures with the study drug were set as independent variables. Odds ratios (ORs) and 95% CIs were calculated. Comparisons of the hospitalization costs were done by the MannWhitney U-test.
Any two-sided P value ,0.05 was considered statistically significant. All statistical analysis was done using the software package IBM Statistics SPSS 20.
Results
Participant flow
A total of 654 patients were screened for eligibility; 600 patients were enrolled, 298 allocated to placebo treatment and 302 to clarithromycin treatment (Figure 1) . No patient was lost to follow-up and all patients allocated to both groups were analysed for primary and secondary outcomes.
Recruitment
Patients were recruited at all study sites between 5 July 2007 and 7 April 2011. The study stopped after enrolment of the last patient.
Baseline data
Both groups of patients were well matched for demographics, underlying conditions, severity of sepsis, microbiology and appropriateness of antibiotic treatment (Table 1) .
Clarithromycin as a moderator of severe sepsis/shock
Overall 28 day mortality was 17.1% (51 deaths out of 298) in the placebo arm and 18.5% (56 deaths out of 302) in the clarithromycin arm (P¼0.671). Forty-two patients died among 109 patients with severe sepsis/shock treated with placebo (38.5%); 44 patients died among 125 patients with severe sepsis/shock treated with clarithromycin (35.2%, P¼0.326 between the two groups). In total, 54 patients had septic shock and MODS. Of these patients, 26 were treated with placebo, of whom 19 died (73.1%). Another 28 patients with septic shock and MODS were treated with clarithromycin; 15 died (53.6%, P¼0.020 between the two groups). The RR for death due to septic shock and MODS was 6.21 (95% CI: 4.16-9.27) in the placebo group and 3.58 (95% CI: 2.29-5.59) in the clarithromycin group (P¼0.036 with the Altman-Bland interaction test).
Subgroup analysis to investigate the interaction of clarithromycin with specific organ failures is presented in Figure S1 and in Tables S1 and S2 (available as Supplementary data at JAC Online).
Secondary endpoints
The median time until resolution of the infection was 5 days in both arms (P ¼ 0.109 between groups). Analysis involving patients with uncomplicated sepsis (n¼ 189 of the placebo arm and n¼177 of the clarithromycin arm) showed that median time until resolution of the infection was 4 days in either group (P ¼0.120 between groups). However, when analysis involved patients with severe sepsis/shock (n¼109 of the placebo arm and n¼ 125 of the clarithromycin arm), it was found that the median time until resolution of infection was 10 days in placebo-treated patients and 6 days in clarithromycin-treated patients (P¼ 0.037, Figure 2 ).
MODS developed after study enrolment in 28 patients allocated to placebo (9.4%) and in 41 patients allocated to clarithromycin Clarithromycin for the therapy of sepsis 1113 JAC (13.6%, P ¼ 0.125). Median time to development of MODS was 6 and 5 days, respectively (P ¼ 0.535).
Effect of clarithromycin on the cost of hospitalization
The cost of hospitalization was analysed between the two arms only for survivors (total¼493: placebo¼247 and clarithromycin¼246). The median cost of hospitalization for survivors treated with placebo was 3383.5 euros/patient; it was significantly decreased to 2269.3 euros/patient for survivors treated with clarithromycin (P ¼ 0.044, Figure 3 ).
Adverse events
The distribution of SAEs was similar between patients receiving placebo (1.3%) and patients treated with clarithromycin (0.7%, P ¼ 0.502) ( Table 2 ). The rate of non-SAEs was greater in the clarithromycin arm that in the placebo arm. These involved greater incidences of pain at the infusion site and of superficial thrombophlebitis (Table 2 ).
Discussion
In this study, we found that intravenous clarithromycin administered for 4 days consecutively did not affect overall mortality. However, a significant decrease of mortality and of the RR for death due to septic shock and MODS was found. This confirms a similar decrease of the risk of death for patients with septic shock and MODS as that reported in our previous randomized clinical study in patients with VAP. 7 The number of hospitalizations for sepsis is steadily increasing worldwide, 12 generating a shortage of ICU beds and considerable health costs. Reported findings should be regarded in light of these unmet needs, since treatment with clarithromycin decreased the time until resolution of infection among the more severe patients and reduced the cost of hospitalization.
Apparently, the benefit of clarithromycin is not due to its antimicrobial action but rather to its immunomodulatory effect. One might speculate that clinical efficacy is a consequence of the antiinflammatory effect in the lung where macrolides tend to accumulate. In our randomized trial 7 in patients with VAP and sepsis in which a 3 day course of clarithromycin also decreased the risk of Giamarellos-Bourboulis et al. 
Continued
Clarithromycin for the therapy of sepsis 1115 JAC death in the most severely ill patients with MODS and cardiovascular failure, the systemic host response was modulated and the effect was not only limited to the lung tissue. This is supported by a study we recently published, 13 in which we found considerable reversal of immunoparalysis of circulating monocytes by the end of the 3 day treatment course. The potency of monocytes to antigen presentation was improved and the ratio of circulating interleukin-10 to tumour necrosis factor-a, which is an index of immunoparalysis, was decreased. This effect of clarithromycin on immunoparalysis was evident within the most severe cases with septic shock and MODS. 13 Within the spectrum of sepsis sufferers, patients with severe sepsis present with immunoparalysis at a higher rate than patients with uncomplicated sepsis.
14 This may explain why the benefit from treatment with clarithromycin related to the reversal of immunoparalysis is most striking in the most severe cases.
Recently, a retrospective analysis of the efficacy of administered antibiotics in a cohort of 235 patients with acute lung injury was published. 15 The results are in line with the current findings. As the analysis indicated, 180 day mortality was significantly reduced in patients receiving a macrolide compared with patients on non-macrolide antibiotics. This was also accompanied by earlier weaning from mechanical ventilation. 15 Benefit from the administration of macrolides was also shown for the most severe cases of CAP, often accompanied by respiratory failure. A recent meta-analysis of 18 observational studies of patients hospitalized with CAP proved survival benefit from macrolide treatment compared with non-macrolide containing regimens. 16 Another retrospective analysis of patients with severe CAP denoted a significant survival benefit from macrolide treatment even for cases caused by macrolide-resistant Streptococcus pneumoniae.
5
It should be underscored that benefit from the studied intervention was not shown when analysis involved the total enrolled population. Decrease of mortality and earlier resolution of infection were found among the more severe cases. However, the intervention with clarithromycin is very cheap as compared with most drugs that have been investigated as modulators of the inflammatory response. This intervention was also proved to be safe. Despite the incidence of one episode of acute myocardial infarction in the clarithromycin arm that should be considered in light of the existing awareness for the cardiovascular toxicity of macrolides, 17 overall safety analysis did not disclose any harm from this intervention. The significant decrease of the cost of hospitalization (shown in Figure 3 ) and the safety of the intervention should encourage its use.
In summary, intravenous clarithromycin did not change the mortality of the overall study population. However, treatment with clarithromycin shortened the time until infection resolution among the more severely ill patients and decreased the hospitalization costs among survivors. Subgroup analysis showing survival benefit among patients with septic shock and MODS strongly encourages the conduct of a future clinical trial to fully decipher the role of clarithromycin as adjunctive therapy in more severely ill patients. Clarithromycin for the therapy of sepsis
